Ocular Therapeutix Inc

NASDAQ:OCULUnited States

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Contact Information

Headquarters

15 Crosby DriveBEDFORD, MA, United States 01730

Phone

781-357-4000

Fax

781-357-4001

Executives

Executive Chairman of the Board, President, Chief Executive Officer

Pravin Dugel

Chief Financial Officer

Donald Notman

Chief Technical Officer

Peter Jarrett

Chief Scientific Officer

Jeffrey Heier

General Counsel

Philip Strassburger